Southwest Virginia Wildlife Center rehabilitating bobcat kitten
ROANOKE, Va. (WFXR) — The Southwest Virginia Wildlife Center has received its first bobcat kitten of the year, and just the third in the past three years.
It was picked up in Floyd on May 21, after it was discovered near its mother, who had been hit and killed by a car.
'Luckily, he did get away from that incident and he has no major injuries,' said Southwest Virginia Wildlife Center volunteer coordinator Catherine McGrath. 'The vets have looked over him and he's in fantastic health. All he's going to need as we raise him are a couple vaccinations.'
The center is working to rehabilitate him and is targeting a spring 2026 release date.
'He's going to be here for a very long time because that's how long it's going to take him to essentially grow up and be large enough to survive while in the wild,' said McGrath.
Southwest Virginia Wildlife Center receives first-ever rare Eastern Spotted Skunk
He has to be fed a specialized formula every two-to-three hours, and staff have to wear full protective gear when interacting with him because of how susceptible big cats are to COVID-19.
Staff members are also working hard to avoid having the animal bond with them, a process they say would complicate things upon its release back into the wild.
'Because the bobcat is going to take about a half a year to ween, that's a lot of interaction with people and not a lot of interaction with another of his own species,' said McGrath. 'So, what we want to do is mitigate him associating us with food and care.'
She also said the Center is actively looking for another bobcat kitten in need of rehabilitation so that the two can grow up as a pair.
'You never want to raise any sort of baby alone,' said McGrath. 'You want to raise them in pairs because that reduces the risk of habituation.'
The whole rehab process is an expensive one, and the Southwest Virginia Wildlife Center says it is looking for some assistance in the form of donations.
'By the time we're getting him ready for release, he's eating four times more than the average house cat,' said McGrath. 'And when you add that up to a year of that sort of care, that is thousands of dollars of specialized food for him.'
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Fraudulent OB/GYN sentenced to 10 years in prison
CHICAGO — A fraudulent OB/GYN, who pleaded guilty last summer for bilking Medicaid and private insurance, has been sentenced to 10 years in prison. Dr. Mona Ghosh owned Progressive Women's Healthcare, located in Hoffman Estates, and was accused of submitting fraudulent claims to Medicaid and other private insurance companies from 2018 to 2022. A total of 17 women spoke during the federal sentencing hearings, which concluded Monday morning after being adjourned on May 29. Several women told stories of how Ghosh charged their insurance companies for visits that didn't happen. Others described the unnecessary tests and procedures she performed. 'I felt like she supported me. In turn, when I'm finding the medical bills coming back for things that never happened, she fed on my vulnerability, on my weakness,' a woman said. Several women shared that they went to Ghosh for a routine pap smear, or cervical cancer screening, and were told results were abnormal. Fearful that they could have cancer, they agreed to get a biopsy. Witnesses said while they were sedated, Ghosh performed other procedures instead, including ones they said have affected their fertility. 17 women share emotional experiences during sentencing of fraudulent OB/GYN Ghosh directed her own employees to submit the fraudulent claims as well. She admitted in the plea agreement that she is accountable for more than $1.5 million. The judge Monday ordered restitution to insurance providers of $1.5 million. Restitution to the victims was ordered in the amount of $605.02. The judge explained that he could only impose restitution to patients based on actual losses for unnecessary and unwanted procedures under specific situations. She has surrendered her medical license and must serve a minimum of two years before being eligible for supervised release. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
20 minutes ago
- Yahoo
Black Kids Are 5 Times More Likely to Get Severe COVID. Now Vaccines Are Being Cut.
The Trump administration has declared an end to COVID-19 vaccine recommendations for children and pregnant people, and health experts have a warning: This is a threat to Black communities. U.S. Health and Human Services Secretary Robert F. Kennedy Jr., who oversees the Centers for Disease Control and Prevention, announced the decision on May 27 and said vaccine guidance would now focus solely on adults over 65 and those with high-risk conditions, effective immediately. By June 3, Dr. Lakshmi Panagiotakopoulos stepped down from her role helping lead the agency's COVID-19 vaccine advisory group, saying she could no longer support decisions that put pregnant people and children at risk. Before the changes took effect, COVID-19 vaccines were recommended for anyone 6 months and older. Kennedy did not offer a scientific rationale for the new recommendations. For Black Americans, the policy shifts are more than bureaucratic changes, according to Oni Blackstock, a physician and founder of Health Justice, a racial and health equity consulting practice. 'These new guidelines don't exist in a vacuum,' she said. 'Limiting booster eligibility risks further compromising the already fragile health status of many Black Americans.' Black Americans are 1.5 times more likely to contract COVID-19 and four times more likely to be hospitalized, according to the Centers for Medicare & Medicaid Services. Research from the Center for Primary Care at Harvard Medical School found that Black children are more than five times as likely to die from the virus. An estimated 165,000 to 220,000 Black Americans have died from COVID-19, according to data compiled by the APM Research Lab. According to a 2023 report from the U.S. Census Bureau, nearly 32% of Black Americans who contracted COVID-19 also experienced long COVID symptoms. The U.S. Food and Drug Administration cited a lack of evidence that annual boosters are needed by healthy, low-risk adults. However, Blackstock, a primary care and HIV physician, said the policy change marks a significant departure from past years when vaccines were broadly recommended and federally funded. 'This contradicts recent CDC data showing that the 2024–2025 boosters benefit people 18 years and older, especially early after vaccination,' she added. Blackstock noted that many Black Americans already struggle with health care access due to systemic barriers like a lack of insurance and residential segregation. 'When these combine with more restrictive vaccine guidelines,' she said, 'it becomes even harder for Black Americans to get boosters and worsens existing health disparities.' These barriers also deepen historic mistrust in health care, said Jerry Abraham, a family and community medicine physician. Abraham, who is director of the CDU-KEDREN Mobile Street Medicine program in Los Angeles, said the history of medical racism and continued treatment disparities fuel skepticism toward public health. Even as boosters offer real benefits, he said, many remain hesitant or disconnected from resources that ensure protection. 'If children and pregnant women are no longer recommended for vaccination, will grandma still go to CVS and get it herself?' he said. Abraham added that in an era where health care professionals can no longer trust the updated guidelines from federal agencies, it's deeply concerning and a reminder that Black communities must once again rely on themselves. For answers about what comes next, read on. Aisha Harris, a family medicine physician in Flint, Michigan, told Capital B that limiting access to COVID-19 vaccines for healthy adults exposes high-risk groups like seniors and those who are immunocompromised. 'Reduced protection in healthy people increases their risk of being infected by COVID and of being a carrier,' said Harris, who owns the direct primary care clinic Harris Family Medicine. 'When more people are contagious, with or without symptoms, they have a higher chance of infecting others around them, including in their household or those they are taking care of as caregivers.' She warned this undermines community immunity. Without widespread coverage, even eligible groups face elevated risks. FDA officials say the new approach mirrors those taken by Australia and several European nations that limit vaccines to older or high-risk adults. But some critics argue the shift ignores U.S. disparities and bypasses standard CDC procedures. You can pay out of pocket, but it could cost up to $200. If the CDC doesn't recommend vaccines, Abraham said health plans are much less likely to cover them, since insurers typically follow CDC guidance. Yes, COVID-19 vaccines have already undergone extensive clinical trials before being authorized for public use. The FDA says it will require longer clinical trials before approving updated shots for healthy kids and adults, with studies lasting at least six months, likely delaying fall approvals. The CDC's vaccine advisory committee is expected to vote on fall vaccine recommendations in late June, but it's unclear how much influence it will have over the newly announced changes. High-risk conditions for COVID-19 vaccine eligibility generally include chronic kidney disease, chronic lung diseases, asthma, diabetes, immunocompromised states (from cancer treatment, organ transplant, HIV, etc.), heart conditions, Alzheimer's disease, obesity, sickle cell disease, smoking, and stroke or cerebrovascular disease. Yes. Studies show COVID-19 vaccination, including boosters, reduces the risk of severe illness and may lower the chances of developing long COVID symptoms after infection. The post Black Kids Are 5 Times More Likely to Get Severe COVID. Now Vaccines Are Being Cut. appeared first on Capital B News.
Yahoo
31 minutes ago
- Yahoo
KLOTHO NEUROSCIENCE, INC. ANNOUNCES AN APPROACH TO INCREASE LONGEVITY AND HEALTHY LIFE SPAN - REPLACE A SILENCED GENE CALLED ALPHA-KLOTHO ("α-KLOTHO")
Recent clinical and pre-clinical studies and analysis indicates the potential to increase lifespan and reduce age-associated degeneration in multiple organ systems has be realized with a focus on the human gene called Klotho. NEW YORK, June 9, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a U.S.-based biogenetics company announced the findings of pre-clinical studies indicating the potential of elevating Klotho gene expression to simultaneously reduce the age-associated degeneration in multiple organs, increasing both life and health span. Pioneering discoveries by Professor Makoto Kuro-O in 1997 showed that Klotho concentrations in the blood were directly associated with lifespan of mammals – the lower the Klotho blood levels the shorter the lifespan. Kuro-O's laboratory then published the first evidence that genetic over expression of the full-length form of Klotho in mice, increased in lifespan of mice of up to 30%-40% longer compared to the normal mouse lifespan. Since then, the Klotho protein has gained much attention because of its ability to influence key biological pathways involved in metabolism, inflammation and tissue repair, which are closely linked to the aging process. A series of experiments led by Joan Roig-Soriano and colleagues, published in the February 2025 edition of Molecular Therapy, highlights the promising role of the naturally occurring secreted form of the Klotho protein ("s-KL") and its effects on healthy aging mice and mice with a rapidly aging phenotype. Key observations were that, while aging is a major risk factor for many pathologies, including cognitive decline, neuroinflammation, sarcopenia, and osteoporosis, the secreted protein s-KL has emerged as a potentially promising therapeutic anti-aging molecule due to its many biological effects involving multiple pathways related to cell injury, stress, and inflammation. The s-KL was administered using an adeno-associated virus serotype 9 delivery vector (AAV9) that expressed the secreted KL protein isoform and efficiently increased the concentration of s-KL in serum, resulting in a 20% increase in lifespan. Dr. Joseph Sinkule, the CEO of Klotho Neurosciences (KLTO) commented that "KLTO has secured an exclusive worldwide license for s-Kl from Universitat Autònoma de Barcelona (UAB) and Institució Catalana de Recerca i Estudis Avançats (ICREA) in Spain. As a result, we have the exclusive use of patents issued in the USA, Europe, and China covering a secreted splice variant of mammalian Klotho referred to as s-KL, as a treatment for neurodegenerative and age -related disorders. Professor Makoto Kuro-O is also a scientific advisor to KLTO. This recently published paper provides further credence to our development of s-KL as a treatment to reduce age-associated degeneration where, as a company, KLTO has a particular focus on neurodegenerative diseases such as ALS, Alzheimer's and Parkinson's disease. The results disclosed in the paper show the potential of elevating s-KL protein expression, resulting in the reduction of age-associated degeneration in multiple organs, increasing both life and health span". About Klotho Neurosciences, Inc. Klotho Neurosciences, Inc. (NASDAQ: KLTO), is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the "anti-aging" human Klotho gene (s-KL), and it's novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's, and Parkinson's disease. The company's current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. The company is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization. For more information, contact:Investor Contact and Corporate Communications - Jeffrey LeBlanc, CFOjeff@ Website: Forward-Looking Statements: This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company's future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company's inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the "SEC") from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. Copies of these documents are available on the SEC's website, All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law. View original content to download multimedia: SOURCE Klotho Neurosciences, Inc.
